Modification of Amniotic Membrane as a Depot Carrier for Bevacizumab – An In-Vitro Model for a Slow Release Mechanism

References

• Seitz B, Resch MD, Schlotzer-Schrehardt U, Hofmann-Rummelt C, Sauer R, Kruse FE. Histopathology and ultrastructure of human corneas after amniotic membrane transplantation. Arch Ophthalmol 2006;124:1487–1490
   PubMedGoogle Scholar
• Touhami A, Grueterich M, Tseng SC. The role of NGF signaling in human limbal epithelium expanded by amniotic membrane culture. Invest Ophthalmol Visual Sci 2002;43:987–994
   PubMed Web of Science ®Google Scholar
• Solomon A, Rosenblatt M, Monroy D, Ji Z, Pflugfelder SC, Tseng SC. Suppression of interleukin 1alpha and interleukin 1beta in human limbal epithelial cells cultured on the amniotic membrane stromal matrix. Brit J Ophthalmol 2001;85:444–449
   PubMed Web of Science ®Google Scholar
• Lee SB, Li DQ, Tan DT, Meller DC, Tseng SC. Suppression of TGF-beta signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. Curr Eye Res 2000;20:325–334
   PubMed Web of Science ®Google Scholar
• Kim JC, Tseng SC. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. Kor J Ophthalmol 1995;9:32–46
   PubMedGoogle Scholar
• Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17:611–613
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Seitz B, Dana MR, Streilein JW. Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options. Ophthalmol: Zeitschr Deutschen Ophthalmol Gesellschaft 2003;100:292–299 (Angiogenese und Lymphangiogenese in der Hornhaut. Pathogenese, klinische Bedeutung und Therapieoptionen)
   Google Scholar
• Regenfuss B, Bock F, Parthasarathy A, Cursiefen C. Corneal (lymph)angiogenesis from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 2008;6:191–201
   PubMedGoogle Scholar
• Bachmann B, Taylor RS, Cursiefen C. The association between corneal neovascularization and visual acuity: a systematic review. Acta ophthalmologica 2011; doi: 10.1111/j.1755-3768.2011.02312.x. [Epub ahead of print]
   Google Scholar
• Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Visual Sci 1996;37:2485–2494
   PubMed Web of Science ®Google Scholar
• Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242–249
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Wenkel H, Martus P, Langenbucher A, Nguyen NX, Seitz B, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefe's Arch Clin Exp Ophthalmol 2001;239:514–521
   PubMed Web of Science ®Google Scholar
• Nguyen NX, Seitz B, Martus P, Langenbucher A, Cursiefen C. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Amer J Ophthalmol 2007;144:318–319
   PubMed Web of Science ®Google Scholar
• Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Visual Sci 1998;39:18–22
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Visual Sci 2007;48:2545–2552
   PubMed Web of Science ®Google Scholar
• Keating AM, Jacobs DS. Anti-VEGF treatment of corneal neovascularization. Ocular Surf 2011;9:227–237
   PubMed Web of Science ®Google Scholar
• Regenfuss B, Bock F, Bachmann B, Konig Y, Hos D, Parthasarathy A, et al. Topische antiangiogene therapie an der hornhaut. sicherheit und effektivitat [Topical inhibition of angiogenesis at the cornea. Safety and efficacy]. Ophthalmol: Zeitschr Deutschen Ophthalmol Gesellschaft 2009;106:399–406
   Google Scholar
• Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocular Surf 2012;10:67–83
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Bock F, Horn FK, Kruse FE, Seitz B, Borderie V, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009;116:1630–1637
   PubMed Web of Science ®Google Scholar
• Chau DY, Brown SV, Mather ML, Hutter V, Tint NL, Dua HS, et al. Tissue transglutaminase (TG-2) modified amniotic membrane: a novel scaffold for biomedical applications. Biomed Mater 2012;7:045011
   Web of Science ®Google Scholar
• Koizumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. Curr Eye Res 2000;20:173–177
   PubMed Web of Science ®Google Scholar
• Thomasen H, Pauklin M, Noelle B, Geerling G, Vetter J, Steven P, et al. The effect of long-term storage on the biological and histological properties of cryopreserved amniotic membrane. Curr Eye Res 2011;36:247–255
   PubMed Web of Science ®Google Scholar
• Kawano Y, Furukawa Y, Karakida S, Kira N, Ishii T, Narahara H. Regulation of interleukin-1alpha and tumor necrosis factor-alpha-induced interleukin-8 production by amnion-derived (WISH) cells. Clin Exp Obstetr Gynecol 2012;39:43–48
   PubMed Web of Science ®Google Scholar
• Mencucci R, Menchini U, Dei R. Antimicrobial activity of antibiotic-treated amniotic membrane: an in vitro study. Cornea 2006;25:428–431
   PubMed Web of Science ®Google Scholar
• Mencucci R, Paladini I, Menchini U, Gicquel JJ, Dei R. Inhibition of viral replication in vitro by antiviral-treated amniotic membrane. Possible use of amniotic membrane as drug-delivering tool. Brit J Ophthalmol 2011;95:28–31
   PubMed Web of Science ®Google Scholar